No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALRN Aileron Therapeutics
- 4.1600
- -0.3900-8.57%
Close May 1 16:00 ET
- 4.3500
- +0.1900+4.57%
Post 16:26 ET
70.17MMarket Cap-1216P/E (TTM)
4.5000High3.7000Low483.85KVolume4.3100Open4.5500Pre Close2.00MTurnover2.90%Turnover RatioLossP/E (Static)16.87MShares7.420052wk High10.20P/B69.51MFloat Cap1.010052wk Low--Dividend TTM16.71MShs Float309.6000Historical High--Div YieldTTM17.58%Amplitude1.0100Historical Low4.1330Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Aileron Therapeutics(ALRN.US) 10% Shareholder Sells US$139.1K in Common Stock
$Aileron Therapeutics(ALRN.US)$ 10% Shareholder UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO sold 31,151 shares of common stock on Apr 29, 30, May 1, 2024 at an average price of $4.465 for a
Express News | Aileron Therapeutics Inc: Entered Into an Underwriting Agreement With Titan Partners Group LLC, as Underwriter
Express News | Aileron Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of an Underwritten Registered Direct Offering of 4,273,505 Shares and Accompanying Warrants at a Combined Offering Price of $4.68
Express News | Aileron Therapeutics Prices 4,273,505 Offering Of Shares And Accompanying Warrants At Combined Offering Price Of $4.68
Express News | Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced at-the-Market Under Nasdaq Rules of up to Approximately $40 Million
Express News | Aileron Therapeutics Inc: Results Show Lti-03 to Be Generally Well-Tolerated With No Serious Adverse Events (Saes) Reported
Comments
$Aileron Therapeutics(ALRN.US$
NEWS
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
NEWS
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
$Aileron Therapeutics(ALRN.US$
NEWS
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics, Inc. announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in IPF. Low-dose LTI-03 showed reductions in profibrotic proteins, increased expression of biomarkers, and was well-tolerated. Positive trends were observed in seven out of eight biomarkers. Data from Cohort 2 is expec...
NEWS
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics, Inc. announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in IPF. Low-dose LTI-03 showed reductions in profibrotic proteins, increased expression of biomarkers, and was well-tolerated. Positive trends were observed in seven out of eight biomarkers. Data from Cohort 2 is expec...
Make a note!
$Aileron Therapeutics(ALRN.US$ Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg